Type 1 diabetes and engineering enhanced islet transplantation.
Adv Drug Deliv Rev
; 189: 114481, 2022 10.
Article
em En
| MEDLINE
| ID: mdl-36002043
ABSTRACT
The development of new therapeutic approaches to treat type 1 diabetes mellitus (T1D) relies on the precise understanding and deciphering of insulin-secreting ß-cell biology, as well as the mechanisms responsible for their autoimmune destruction. ß-cell or islet transplantation is viewed as a potential long-term therapy for the millions of patients with diabetes. To advance the field of insulin-secreting cell transplantation, two main research areas are currently investigated by the scientific community (1) the identification of the developmental pathways that drive the differentiation of stem cells into insulin-producing cells, providing an inexhaustible source of cells; and (2) transplantation strategies and engineered transplants to provide protection and enhance the functionality of transplanted cells. In this review, we discuss the biology of pancreatic ß-cells, pathology of T1D and current state of ß-cell differentiation. We give a comprehensive view and discuss the different possibilities to engineer enhanced insulin-secreting cell/islet transplantation from a translational perspective.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Transplante das Ilhotas Pancreáticas
/
Diabetes Mellitus Tipo 1
/
Células Secretoras de Insulina
/
Insulinas
Limite:
Humans
Idioma:
En
Revista:
Adv Drug Deliv Rev
Ano de publicação:
2022
Tipo de documento:
Article